Thromboelastography (TEG) Reference Range Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

159 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As part of a system wide reagent verification plan Haemoscope Corporation will be running a study to verify the reference intervals of many of the reagents. Reference intervals will be constructed following the guidelines set out in CLSI document C28-A3c. This guideline calls for a reference interval to be constructed from at least 120 donors. Some reagents currently have ranges in place based on fewer donors than that stated in the guideline. This procedure will provide additional testing results to meet the requirements outlined in the CLSI guideline. Reagents that currently have no reference intervals will be tested and will include a minimum of 146 donors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

NCT06261580

Healthy

COMPLETED

Procedure For The Reference Range Study For Absolute MA

NCT02110576

Transmission, Blood, Recipient/Donor

COMPLETED

Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

NCT02798328

DOAC Eligible Subjects

COMPLETED

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125

Surgery

COMPLETED

Equivalency Study of the TEG and CORA Hemostasis Systems

NCT01790386

Heart Disease Focus is on Testing Performance of CORA Hemostasis System.

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coagulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female over the age of 18 years.

Exclusion Criteria

* Genetic bleeding disorders
* Currently Pregnant
* Oral Contraceptives
* On anti-coagulants or anti-platelet therapy
* Took ASA (Acetylsalicylic Acid)within 1 week prior
* Recent surgery (within 4 weeks)
* Recent injury leading to substantial bruising (within 2 weeks)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes